Sign inJoin waitlistJoin the waitlist

Grace Dy

Director of Translational Research for Thoracic Medicine · ROSWELL PARK CANCER INSTITUTE

Credentials: · · · ·

History

University at Buffalo School of Medicine
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2004–2007
Internal Medicine
Mayo Clinic College of Medicine and Science
2000–2003
Chinese General Hospital 1999
1998–1999
UNIV OF SANTO TOMAS, MANILA
1994–1998

Research

Sotorasib for Lung Cancers with KRAS p.G12C Mutation
New England Journal of Medicine · 2021 · 1,513 citations
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
New England Journal of Medicine · 2020 · 1,421 citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2,…
The Lancet Oncology · 2015 · 1,216 citations

Alex Adjei
55 papers
Hongbin Chen
15 papers
Wen Ma
14 papers
Sai Yendamuri
10 papers
Marc Ernstoff
9 papers
Chukwumere Nwogu
8 papers
Julian Molina
8 papers
Todd Demmy
8 papers
Carl Morrison
7 papers
Igor Puzanov
7 papers
SA
Steven Alberts
7 papers
SS
Steven Schild
7 papers

Grants

Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay
National Cancer Institute · R01
PI · $3.1M · State University of New York at Buffalo
2022–2027
Exosomal Thomsen-Friedenreich Glycoantigen as a New Biomarker for Lung Cancer Screening and Early Detection
National Cancer Institute · R21
PI · $427.5K · State University of New York at Buffalo
2022–2025

Clinical trials

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
Principal investigator · Not yet recruiting · Phase 2
Roswell Park Cancer Institute
2026–2029
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
Principal investigator · Withdrawn · Phase 1
Roswell Park Cancer Institute
2024–2027
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 2
Roswell Park Cancer Institute
2021–2027
Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 2
Roswell Park Cancer Institute
2020–2026